Doctor

Topics: Innovation, Research, New York City Pages: 10 (2562 words) Published: April 4, 2013
2011

Pfizer’s Centers for Therapeutic Innovation By Dr. Minna Allarakhia Editor, CanBiotech Inc. Director, BioEndeavor Network

April 2011 @CanBiotech Inc.

2011

Open Innovation Case Study: Pfizer’s Centers for Therapeutic Innovation

Pfizer’s Centers for Therapeutic Innovation
By Dr. Minna Allarakhia Editor, CanBiotech Inc. Director, BioEndeavor Network

Abstract Pfizer recently announced the formation of a network of academic collaborators to accelerate the translation of basic science into biologics-based drugs. Pfizer anticipates establishing local Centers at each partner site enabling Pfizer and Academic Medical Center teams to work closely together. The University of California, San Francisco (UCSF), has signed on as the first of multiple partners. The partnerships will follow a venture capital-funded biotechnology start-up model, whereby Pfizer funds preclinical and clinical development programs and offers equitable intellectual property and ownership rights. Pfizer has the goal of expanding the Centers to Europe and Asia in 2012. Assuming eight projects per CTI, this could bring dozens of differentiated entities against targets into Pfizer’s pipeline. 1.0 Introduction Pfizer recently announced the formation of a network of academic collaborators to accelerate the translation of basic science into biologics-based drugs. According to Mikael Dolsten, M.D., Ph.D., president of Pfizer Worldwide Research & Development, the Centers represents a novel open innovation paradigm, combining the competencies of top academic research institutions with Pfizer's leading drug development capabilities and research technologies. (Pfizer, 2010) The Centers for Therapeutic Innovation (CTI) will initially focus on collaborations within the U.S. Pfizer expects to expand into Europe and Asia in 2012. Each Center will be governed by a Joint Steering Committee (JSC)

comprised of Pfizer and Academic Medical Center (AMC) representatives who will provide leadership and evaluate the success of each program through discovery and early stage clinical development. Through this innovation model, Pfizer will have the opportunity to broaden its pipeline with novel candidate drugs to treat diseases—addressing unmet medical need. (Pfizer, 2010) 2.0 The Partners The University of California, San Francisco (UCSF), has signed on as the first of multiple partners in Pfizer’s Global Centers for Therapeutic Innovation. UCSF will receive up to $85 million in research support and milestone payments over the course of the five-year partnership. Pfizer will open labs adjacent to the UCSF campus, where Pfizer scientists will work alongside university researchers to find new biologics targeting a range of diseases. Although Pfizer has an R&D site in South San Francisco, proximity to the UCSF campus is seen as critical to fostering an effective intellectual exchange according to Anthony J. Coyle, who will head CTI. (Jarvis, 2010) In January of 2011, Pfizer Inc. further announced that seven major research-based medical centers in New York City joined Pfizer’s CTI. The New York medical centers include: Rockefeller University, New York University Langone Medical Center, Memorial Sloan-Kettering Cancer Center, The Mount Sinai Medical Center, Columbia University Medical Center, Albert Einstein College of Medicine of Yeshiva University, and Weill Cornell Medical College. Pfizer has signed a lease at the Alexandria Center for Life Science—providing the company with research space to facilitate its New York Citybased collaborations. The Alexandria Center is a life science park in New York City and home to a number of research organizations and leading life science entities. Its office and laboratory space encourages collaboration and Page 2

©CanBiotech Inc. 2011 Pfizer’s Centers for Therapeutic Innovation

2011

Open Innovation Case Study: Pfizer’s Centers for Therapeutic Innovation

is ideally located to facilitate close working relationships...

References: 1) Allarakhia, M., Kilgour, D.M., Fuller, D., 2010. Modeling the incentive to participate in open source biopharmaceutical innovation. R&D Management 40, 50-66. 2) Bozeman, B., Boardman, C., 2003. Managing the new multipurpose multidisciplinary university research centers: Institutional innovation in the academic community. IMB Center for the Business of Government. 3) Call for Proposals for UCSF-Pfizer Center for Therapeutic Innovation, UCSF, December 2010. 4) Chesbrough, H.W., 2007. Why companies should have open business models. MIT Sloan Management Review 48, 22-28. 5) Chesbrough, H.W., 2003. The era of open innovation. MIT Sloan Management Review 44, 35-41. 6) Corley, E.A., Boardman, P.C., Bozeman, B., 2006. Design and the management of multi-institutional research collaborations: Theoretical implications from two case studies. Research Policy 35, 975-993. 7) Geels, F.W., 2002. Technological transitions as evolutionary reconfiguration processes: a multi-level perspective and a casestudy. Research Policy 31, 1257−1274. 8) Jarvis, L. Pfizer Unveils Academic Network, C&EN, November 2010. 9) Moller, K. K., Svahn, S., 2009. How to influence the birth of new business fields.
Industrial Marketing Management, 38, 450−458. 10) Pfizer Launches Global Centers for Therapeutic Innovation, a Network of Research Partnerships, With University of California, San Francisco, PR Newswire, November 2010. 11) Powell, W.W., Koput, K.K., Smith-Doerr, L., 1996. Inter-organizational collaboration and the locus of innovation: Network of learning in biotechnology. Administrative Science Quarterly 41, 116-145. 12) Rampersad, G., Quester, P., Troshani, I., 2010. Managing innovation networks: Exploratory evidence from ICT, biotechnology and nanotechnology networks. Industrial Marketing Management 39, 793805. 13) Ratner, M, 2011. Pfizer reaches out to academia—again. Nature Biotechnology 29, 3-4. 14) Rockefeller joins Pfizer’s Global Centers For Therapeutic Innovation, The Rockefeller University, April 2011. 15) Roijakkers, N., Hagedoorn, J., 2006. Interfirm R&D partnering in pharmaceutical biotechnology since 1975: Trends, patterns, and networks. Research Policy, 35, 431−446. 16) Seven New York Research Hospitals Join Pfizer’s Centers for Therapeutic Innovation, GEN News, January 2011. 17) www.pfizer.com, 2011.
©CanBiotech Inc. 2011 Pfizer’s Centers for Therapeutic Innovation
Page 7
Continue Reading

Please join StudyMode to read the full document

You May Also Find These Documents Helpful

  • The Doctor Essay
  • Essay on Doctor and Hand
  • doctors dilemma Essay
  • At the Doctors Office Essay
  • Family and Doctor Essay
  • Essay on Dialog "An Appointment with a Doctor"
  • Hemingway's "The Doctor and Teh Doctor's Wife" Essay
  • Essay on The Controversial Issue of Doctor-Assisted Suicide

Become a StudyMode Member

Sign Up - It's Free